Heart 1999;81:148-152 ( February )
Clinical usefulness of 123I
meta-iodobenzylguanidine imaging in predicting the effectiveness of
blockers for patients with idiopathic dilated cardiomyopathy before and
soon after treatment
a Division of
Cardiology, National Cardiovascular Centre, Osaka 565, Japan, b Division of Cardiology, Osaka Dai-ichi Hospital,
6-2-2, Mitejima, Nishiyodogawa-ku, Osaka 555-0012, Japan
Correspondence to: Dr Sasaki.
Accepted for publication 28 September 1998
Objective
To
investigate the value of iodine-123 meta-iodobenzylguanidine (MIBG)
myocardial imaging for defining high risk patients with idiopathic
dilated cardiomyopathy from among candidates for
blocker treatment,
and for predicting functional improvement of the left ventricle in the
early stages of treatment.
Methods
Echocardiographic
indices, neurohormonal measurements, and myocardial MIBG distribution
were assessed at baseline and after one month and three months of
treatment in 27 patients with idiopathic dilated cardiomyopathy.
Patients were classified into two groups, based on whether they reached
a daily dose of > 20 mg of metoprolol without deterioration of heart
failure at three months (group A, n = 20) or not (group B, n = 7).
Results
There
were no significant differences in the echocardiographic indices or
neurohormonal activity at baseline between the two groups, but MIBG
uptake was higher, and the washout rate lower, in group A than in group
B. After one month, though there were no significant changes in
echocardiographic and neurohormonal variables, the heart to mediastinal
(H/M) ratio on the delayed image was increased in group A but not in
group B. In group A, the degree of increase in the H/M ratio on the
delayed image after one month was also correlated with the degree of
reduction in plasma concentrations of noradrenaline after three months.
Conclusions
MIBG
myocardial imaging may be useful for predicting the outcome of
blocker treatment for heart failure patients with idiopathic dilated cardiomyopathy.
blockers;
MIBG
© 1999 by Heart
This article has been cited by other articles:
-
Tsukamoto, T., Morita, K., Naya, M., Inubushi, M., Katoh, C., Nishijima, K., Kuge, Y., Okamoto, H., Tsutsui, H., Tamaki, N.
(2007). Decreased Myocardial {beta}-Adrenergic Receptor Density in Relation to Increased Sympathetic Tone in Patients with Nonischemic Cardiomyopathy. JNM
48: 1777-1782
[Abstract] [Full Text] -
Kasama, S., Toyama, T., Kumakura, H., Takayama, Y., Ichikawa, S., Suzuki, T., Kurabayashi, M.
(2003). Effect of spironolactone on cardiacsympathetic nerve activity and left ventricular remodeling in patients with dilated cardiomyopathy. J Am Coll Cardiol
41: 574-581
[Abstract] [Full Text] -
Kasama, S., Toyama, T., Kumakura, H., Takayama, Y., Ichikawa, S., Suzuki, T., Kurabayashi, M.
(2002). Spironolactone Improves Cardiac Sympathetic Nerve Activity and Symptoms in Patients with Congestive Heart Failure. JNM
43: 1279-1285
[Abstract] [Full Text] -
Kasama, S., Toyama, T., Hoshizaki, H., Oshima, S., Taniguchi, K., Suzuki, T., Kurabayashi, M.
(2002). Dobutamine Gated Blood Pool Scintigraphy Predicts the Improvement of Cardiac Sympathetic Nerve Activity, Cardiac Function, and Symptoms After Treatment in Patients With Dilated Cardiomyopathy*. Chest
122: 542-548
[Abstract] [Full Text]
Register for free content
The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.
Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.
